Aetna : We anticipate a reversal
Entry price | Target | Stop-loss | Potential |
---|
$65.15 |
$0 |
$63.8 |
-100% |
---|
Aetna could regain its upward trend after a contact with the USD 65 support.
According to Surperformance ratings, the group has strong fundamentals, both in terms of business predictability and valuation. Based on current prices, the company is valued at 0.55 times its sales and the P/E ratio is only at 10.87 for the current year, confirming the low valuation of the stock.
Aetna is in bullish trend in the medium and long term. In weekly data, moving averages are well-oriented and limit the downward potential. In the present configuration, the consolidation phase represent a good opportunity to take a long position on Aetna.
Investor could buy the security close to USD 65 to take advantage of a new upward acceleration in the direction of USD 68.25. A stop loss is placed below USD 65.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.